Home
overview

SMi is proud to present its 13th annual Superbugs & Superdrugs conference, due to take place in London on Wednesday 16th & Thursday 17th March 2011.
 

 
About the conference

Antibiotic resistance is a global threat and challenge that encompasses broad political, social and economic implications.

According to a recent EMEA report, resistance among Gram-positive and Gram-negative bacteria is already reaching 25% or more in several EU Member States. The most recent concern is the emergence of Gram-negative bacilli expressing the New Delhi metallo-beta-lactamase (NDM-1), which are resistant to all available antibiotics.

Despite these worrying facts, the late clinical stage antibiotic pipeline is very limited, indeed at its lowest point since the discovery of penicillin in 1928. Furthermore, recent changes in the regulatory expectations and standards for conducting trials of new antibacterial agents have meant current methods of conducting some specialized types of clinical trials are becoming inadequate.

The conference will address:

  • Global trends in infectious disease strategies - Identifying infectious disease threats, commercial opportunities, challenges facing antibiotic drug development and the role of the EC in funding antimicrobial research
  • Responding to multi-resistant organisms - Addressing the threat of carbapenemase producing enterobacterial strains, novel antibiotics to combat MDR organisms and the role of molecular diagnostics in treating MDR organisms, improving therapy and patient outcomes
  • Novel antimicrobial therapeutic approaches & areas -  Investigate the next generation of antimicrobial therapeutics and learn from case studies and development strategies
  • Vaccine, anti-viral and anti-fungal developments - Trends in vaccine development,  the need, opportunities and approaches for novel antifungal therapies and a new paradigm for treating infections and disease caused by HCMV

This conference will build upon a strong scientific reputation, featuring key leaders in the field of antibiotic resistance and drug development, case study focused presentations with a practical theme enabling you to learn from the best.

SMi's 13th annual Superbugs & Superdrugs Conference

 

 Make sure you save the date for our half day pre-conference workshop as well

Associated with the conference there will be a half-day interactive workshop on "Translating Innovation to Success in Antimicrobial Drug Discovery and Development", taking place on 15th of March. This workshop will provide insights into the stages of the antimicrobial drug discovery process with the goal of increasing the probability of success.

Leading this workshop will be Nafsika Georgopapadakou, Anti-infective Research Consultant, Bozena Korczak, Senior Vice President, Chief Development Officer, PolyMedix and also Barry Eisenstein, Senior VP, Scientific Affairs at Cubist Pharmaceuticals. To see more information about the workshop, please see the comprehensive workshop page.


Want to download the brochure?  Click here

Want to register your place? Click here

Sponsorship and exhibition opportunities available - Click here

Make a group booking and save - Click here

A view from the conference chairman:

"The forthcoming Superbugs and Superdrugs meeting in London is especially important in the light of increasing concerns over antibiotic resistance and the relatively poor rate of introduction of new agents into the clinic.  The meeting will provide a timely review of current industrial activities and help to foster cooperation between academic institutions and pharmaceutical companies." 

View the full letter

 

Ian Chopra, University of Leeds, November 2010

All those responsible for research, medical microbiology, antimicrobial therapeutics, clinical development and business development, including:

  • Chief Scientific Officers
  • Senior Vice Presidents
  • Chief Medical Officers
  • Research Scientists
  • Clinical Microbiologists
  • R&D Project Managers
  • Heads of Anti-Infectives Discovery
  • Clinical Trials Managers
  • Principal Scientists
  • Senior Vice Presidents of R&D
  • Business Development Managers
  • Product Managers

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 Overview of the key global trends in infectious disease strategies

Chan Harjivan

Chan Harjivan, Principal, PRTM

  • A comprehensive view of infectious disease threats
  • Globalisation of commercial opportunities
  • Dual use technologies
  • Centres of excellence
  • New sources of government funding for biotech
  • 9:40 Infectious disease drug discovery today - How and where will new antibiotics come from?

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • Where should our efforts be focused?
  • The modern biotech - virtual company
  • Collaborations between academia and the pharmaceutical industry
  • Funding research and development - Private investment or grant funded research
  • Exploring the opportunities for drug discovery using novel collaborative models and approaches
  • 10:10 Morning Coffee

    10:40 Overview of Trends and Issues for Anti-Microbial Development in the United States

    Jennifer Hannesschlager

    Jennifer Hannesschlager, Principal, Tiber Creek Partners

  • Current political and regulatory issues facing those in the antimicrobial space
  • Emerging thoughts and trends around combination therapeutics
  • Opportunities for the establishment of public-private partnerships
  • Forecasting
  • 11:10 European Union support to research on antimicrobial resistance

    Anna Lönnroth

    Anna Lönnroth, Infectious Diseases Unit, DG Research, European Commision

  • Overview of current EC research funding on antimicroibial drug resistance
  • Opportunities for anti-infective R&D within the EC 7th framework programme
  • Research that indirectly supports to the anti-infective R&D pipeline
  • What role should public funding play in anti-infective R&D?
  • 11:40 Chemical mimetics of host defense proteins- a lesson from nature

    Bozena Korczak

    Bozena Korczak, Senior Vice President, Chief Development Officer, PolyMedix Inc.

  • Addressing the development of resistance and treatment of multi-resistant bugs
  • New class of antibiotic - safety and efficacy in clinical studies
  • Opportunities and challenges
  • 12:20 Addressing the threat of carbapenemase producing enterobacterial strains

    David Wareham

    David Wareham, Clinical Senior Lecturer & Honorary Consultant , Centre for Infectious Disease

  • Molecular Epidemiology
  • Clinical Impact
  • Laboratory Detection
  • Treatment options and resistance to agents of 'last resort'
  • 12:50 Networking Lunch

    13:50 Healthcare solutions for multidrug resistant bacterial or fungal related infectious diseases

    Laurent Fraisse

    Laurent Fraisse, Associate Vice President, Discovery Research, Sanofi-Aventis

  • Sanofi-aventis novel strategy
  • Multi stage integration of external innovation
  • Illustrative examples
  • 14:20 The role of molecular diagnostics in addressing multi-drug resistant organisms

    Fred Tenover

    Fred Tenover, Senior Director, Cepheid

  • The limitations of conventional identification and susceptibility testing methods
  • Current and future technologies for rapid detection of resistance
  • Assays performed directly on blood samples, positive blood culture bottles,  respiratory tract specimens, and specimens for sexually transmitted diseases
  • Barriers to the implementation of rapid technologies
  • 14:50 New beta-lactam antibiotics addressing multi-drug resistant Gram-negative bacteria

    Laurenz Kellenberger

    Laurenz Kellenberger, Chief Scientific Officer, Basilea Pharmaceutica

  • "Trojan-horse" antibiotics: exploiting nature's Achilles heel
  • Substrate specificity and inhibitor sensitivity of carbapenemases
  • Activity of BAL30072 against MDR Gram-negative bacteria
  • 15:20 Afternoon Tea

    15:50 The challenge of serious fungal infections: opportunities and approaches for novel therapies

    Neil Ryder

    Neil Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.

  • The need for novel antifungal therapies
  • The current antifungal R&D pipeline and prospects
  • Bacteria and fungi - two different worlds?
  • Novel approaches, targets and technologies
  • Future trends
  • 16:30 Terminase Inhibitors: A new paradigm for treating infections and disease caused by HCMV

    Holger Zimmermann

    Holger Zimmermann, Chief Scientific Officer, Aicuris

  • HCMV: An underserved area in infectious disease therapy with high medical need and "niche-buster" potential
  • Reversed genomics for discovering unused and unusual drug targets
  • AIC246: One of four innovative agents against HCMV: preclinical and clinical results
  • The paradigm shift in controlling HCMV:
  • From pre-emptive therapy towards prophylaxis
  • From no treatment of patients in need towards effective therapy
  • 17:00 Overview of vaccine development - Where are vaccines going?

    Penny Heaton

    Penny Heaton, Head of Clinical Research and Development Clusters, Novartis Vaccines and Diagnostics, Inc.

  • New disease targets
  • New target populations
  • New technologies
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Ian Chopra

    Ian Chopra, Professor of Microbiology, University of Leeds

    9:10 A new twist on antibacterial discovery: Structure based approaches with DNA gyrase

    Michael Gwynn

    Michael Gwynn, Director, Microbiology, Infectious Diseases CEDD, GlaxoSmithKline

  • Brief pipeline review
  • Challenges of antibacterial discovery and HTS based approaches
  • Structure based discovery efforts with DNA gyrase
  • Lead optimisation progress on Gram negative agents vs DNA gyrase
  • Importance of public-private partnerships
  • 9:40 Discovery of new antibacterial agents targeting gram positive infections

    Chester Metcalf

    Chester Metcalf, Vice President, Discovery Chemistry, Cubist Pharmaceuticals

  • Cubist pipeline strategy
  • CB-183,315 Phase 1 study completed
  • Clinical microbiological data supporting 315 as a novel CDAD therapeutic
  • Novel semi-synthetic natural product antibacterials
  • Drug discovery strategies and approaches
  • 10:20 Morning Coffee

    11:00 Chemical mimetics of host defense proteins - antimicrobial activities

    Richard Scott

    Richard Scott, Vice President, Research, PolyMedix, Inc.

  • Drug discovery
  • Mechanism of action
  • Susceptibility profiles
  • 11:30 Antibodies as novel treatment options for ventilator-associated pneumonia

    Michael Rudolf

    Michael Rudolf, Chief Scientific Officer, Kenta Biotech

  • Generation of fully human antibodies from human B-cells
  • Clinical experience with fully human IgM antibodies for treatment of P. aeruginosa VAP
  • Monoclonal antibodies for treatment of VAP caused by S. aureus
  • 12:10 Lead generation against novel antibacterial targets - recent experiences at AstraZeneca

    Jacques Dumas

    Jacques Dumas, Vice-President and Head of Strategy, Infection Innovative Medicines, AstraZeneca R&D Boston

  • Challenges with lead generation and lead optimisation
  • Illustrative examples
  • Lessons learned
  • 12:50 Networking Lunch

    14:10 Unique molecular insights for designing new broad-spectrum antibiotics

    Erin Duffy

    Erin Duffy, Vice President, Discovery Research, Rib-X Pharmaceuticals

  • Structural insights into how antibiotics bind to the ribosome
  • Use of these insights for the design and optimization of completely new antibiotics for broad-spectrum activity, including MDR Gram-negatives
  • Uncovering the molecular features that distinguish delafloxacin from all other fluoroquinolones
  • 14:40 Developing a novel, specific spectrum, oral antibiotic for staphylococcal infections

    Nachum Kaplan

    Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals Inc

  • Bacterial fatty acid synthesis as target for novel antibiotics
  • AFN-1252 has potent, selective activity against all staphylococci including MRSA
  • Selective spectrum predicts reduced antibiotic associated adverse events
  • AFN-1252 is well tolerated in Phase 1 studies
  • Challenges in development of a specific spectrum agent
  • 15:10 Afternoon Tea

    15:40 Novel approaches to anti-bacterial drug discovery

    Progress:

  • Random HTS-based approach has been disappointing
  • Rapidly increasing amount of structural information for established as well as new targets
  • Structure-based methods offer rapid approach to inhibitor discovery
  • Challenges:

  • Inhibitors lacking antibacterial activity
  • Off-target activity and membrane damage
  • High resistance potential for single-target inhibitors
  • Colin Fishwick

    Colin Fishwick, Professor of Medicinal Chemistry, School of Chemistry, University of Leeds

    Alex O'Neill

    Alex O'Neill, Independent Research Fellow, University of Leeds

    16:10 GP-Ceph Heterodimers - A multivalent approach

    Edmund J. Moran

    Edmund J. Moran, Vice President, R&D Project Leader, Theravance

  • Biochemical Insights to Mode of Action
  • Profile of Microbiological Features
  • Clinical Experience to Date
  • 16:50 Interactive Panel Discussion

    Balancing novelty, spectrum, safety, efficacy, economics and regulatory standards

    Barry Hafkin

    Barry Hafkin, Chief Medical Officer, Affinium Pharmaceuticals

    Barry Eisenstein

    Barry Eisenstein, Senior VP, Scientific Affairs / Clinical Professor of Medicine, Cubist Pharmaceuticals / Harvard Medical School

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    17:20 Chairman’s Closing Remarks and Close of Day Two

    +

    Workshops

    Translating Innovation to Success in Antimicrobial Drug Discovery and Development
    Workshop

    Translating Innovation to Success in Antimicrobial Drug Discovery and Development

    Millennium Gloucester Hotel
    15th March 2011
    London, United Kingdom

    Millennium Gloucester Hotel

    Harrington Gardens
    London SW7 4LH
    United Kingdom

    Millennium Gloucester Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.